Boston Partners
BIO icon

Boston Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Boston Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
9,040
+847
+10% +$240K ﹤0.01% 562
2026
Q1 		$2.28M Sell
8,193
-239,419
-97% -$69M ﹤0.01% 561
2025
Q4 		$75M Buy
+247,612
New +$77.3M 0.08% 235

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Boston Partners's BIO Position: Q2 2026 in Review

Boston Partners increased its Bio-Rad Laboratories Class A (BIO) stake by 10% in Q2 2026, buying an estimated $240K and bringing the position to 9,040 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #562.

Boston Partners first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $75M in Q4 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Boston Partners held 9,040 shares of Bio-Rad Laboratories Class A worth $2.65M as of Q2 2026.
  • Boston Partners bought 847 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $240K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Boston Partners's portfolio in Q2 2026, its #562 holding.
  • Boston Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Boston Partners's Bio-Rad Laboratories Class A position peaked at $75M in Q4 2025.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.